<p>The lack of harmonization for microbiome-based clinical studies represents a critical issue for microbiome researchers and stakeholders, although microbiome research and clinical studies on the gut microbiome have been intensively conducted for more than a decade. The selection of a minimum metadata set to be analysed and reported during clinical studies with microbiome outcomes, the identification of reference materials, the definition of standardized sampling procedures and data analysis protocols, and the choice of unified clinical end points are still lacking. The two-round Delphi survey, conducted within the framework of the Horizon Europe Human Microbiome Action (HMA) consortium, aimed to standardize metadata collection, sampling procedures, data generation and sharing, and standard operating procedures for aspects of gut microbiome-based clinical studies beyond outcomes. The process involved 72 scientists and experts worldwide in the first round and 61 experts in the second round, with an 85% participation rate from the first to the second round. On the basis of the outcome of the Delphi survey, the HMA consortium provided 15 recommendations that might be taken up by the community at large to promote coherence and harmonization in the way microbiome clinical research is and will be performed. The recommendations mainly focus on the gut microbiome and diseases associated with the gastrointestinal tract and gut–organ axes.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Multidisciplinary Delphi consensus statement on minimal standards for clinical metadata and end points in microbiome studies

  • Robert Schierwagen,
  • Federica Carraturo,
  • Anandhi Iyappan,
  • Maximilian J. Brol,
  • Celine Druart,
  • Mads Israelsen,
  • Zahra Hassani,
  • Kevin Legent,
  • Yolanda Godoy,
  • Corrado Vecchi,
  • Julie Rodriguez,
  • Ida Falk Villesen,
  • Alexander Jarde,
  • Manimozhiyan Arumugam,
  • Aleksander Krag,
  • Emmanuelle Maguin,
  • Peer Bork,
  • Typas Nassos,
  • Dienty Hendrina Maria Johanna Hazenbrink,
  • Hub Zwart,
  • Laurence Zitvogel,
  • Lisa Derosa,
  • Carolina Alves Costa Silva,
  • Hervé Blottière,
  • Aicha Kriaa,
  • Moez Rhimi,
  • Patrick Veiga,
  • Nicolas Pons,
  • Pierre-Louis Prost,
  • Fay Betsou,
  • Magali Cordaillat-Simmons,
  • Isabelle Boutron,
  • Philippe Ravaud,
  • Dirk Haller,
  • Amira Metwaly,
  • Paul Ross,
  • Paul O’Toole,
  • Aonghus Lavelle,
  • Marcus Claesson,
  • Raphaela Joos,
  • Colin Hill,
  • Andrey Shkoporov,
  • Saba Loftus,
  • Katy Boucher,
  • Arjun Sarathi,
  • Vitalina Morozova,
  • Nicola Segata,
  • Francesco Asnicar,
  • Federica Pinto,
  • Stephan Kampshoff,
  • Joel Doré,
  • Jonel Trebicka,
  • Alessio Fasano

摘要

The lack of harmonization for microbiome-based clinical studies represents a critical issue for microbiome researchers and stakeholders, although microbiome research and clinical studies on the gut microbiome have been intensively conducted for more than a decade. The selection of a minimum metadata set to be analysed and reported during clinical studies with microbiome outcomes, the identification of reference materials, the definition of standardized sampling procedures and data analysis protocols, and the choice of unified clinical end points are still lacking. The two-round Delphi survey, conducted within the framework of the Horizon Europe Human Microbiome Action (HMA) consortium, aimed to standardize metadata collection, sampling procedures, data generation and sharing, and standard operating procedures for aspects of gut microbiome-based clinical studies beyond outcomes. The process involved 72 scientists and experts worldwide in the first round and 61 experts in the second round, with an 85% participation rate from the first to the second round. On the basis of the outcome of the Delphi survey, the HMA consortium provided 15 recommendations that might be taken up by the community at large to promote coherence and harmonization in the way microbiome clinical research is and will be performed. The recommendations mainly focus on the gut microbiome and diseases associated with the gastrointestinal tract and gut–organ axes.